XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Equity (Deficit) (Unaudited) - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Noncontrolling Interest [Member]
Retained Earnings [Member]
Balance at Dec. 31, 2023 $ 11,448,395 $ 2 $ 128,443,882 $ 673,292 $ (117,668,781)
Balance, shares at Dec. 31, 2023   1,690      
Stock-based compensation 40,695 40,695
Restricted common stock grant $ 1 (1)
Restricted common stock grant, shares   40      
Restricted common stock forfeitures $ (1) 1
Restricted common stock forfeitures, shares   (1)      
Net income (loss) (3,943,268) (12,248) (3,931,020)
Balance at Mar. 31, 2024 7,545,822 $ 2 128,484,577 661,044 (121,599,801)
Balance, shares at Mar. 31, 2024   1,729      
Balance at Dec. 31, 2023 11,448,395 $ 2 128,443,882 673,292 (117,668,781)
Balance, shares at Dec. 31, 2023   1,690      
Net income (loss) (14,424,531)        
Balance at Sep. 30, 2024 (2,448,310) $ 3 128,971,707 (1,265,851) (130,154,169)
Balance, shares at Sep. 30, 2024   2,312      
Balance at Mar. 31, 2024 7,545,822 $ 2 128,484,577 661,044 (121,599,801)
Balance, shares at Mar. 31, 2024   1,729      
Stock-based compensation 60,772 60,772
Issuance of common stock 2,529,449 $ 1 2,529,448
Issuance of common stock, shares   311      
Issuance of warrants (2,075,300) (2,075,300)
Net income (loss) (5,010,551) 73,310 (5,083,861)
Balance at Jun. 30, 2024 3,050,191 $ 3 128,999,496 734,354 (126,683,662)
Balance, shares at Jun. 30, 2024   2,040      
Stock-based compensation (27,789) (27,789)
Issuance of common stock upon exercise of pre-funded warrants, shares   287      
Restricted common stock forfeitures, shares   (15)      
Net income (loss) (5,470,712) (2,000,206) (3,470,507)
Balance at Sep. 30, 2024 (2,448,310) $ 3 128,971,707 (1,265,851) (130,154,169)
Balance, shares at Sep. 30, 2024   2,312      
Balance at Dec. 31, 2024 (9,013,430) $ 3 129,697,781 (1,198,286) (137,512,928)
Balance, shares at Dec. 31, 2024   3,204      
Stock-based compensation 13,824 13,824
Sale of common stock and pre-funded warrants, net of offering costs 14,308,300 $ 4 14,308,296
Sale of common stock and pre-funded warrants, net of offering costs, shares   3,925      
Issuance of common stock upon exercise of pre-funded warrants $ 49 (49)
Issuance of common stock upon exercise of pre-funded warrants, shares   49,075      
Fair value of pre-funded warrants issued along with sale of common stock (1,803) (1,803)
Transition of warrant derivative liability to equity upon exercise of pre-funded warrants 1,803 1,803
Issuance of common stock upon exercise of June 2024 Series B common stock purchase warrants 3,793 $ 2 3,791
Issuance of common stock upon exercise of June 2024 Series B common stock purchase warrants, shares   1,897      
Transition of warrant derivative liability to equity upon exercise of Series B warrants 1,989,806 1,989,806
Net income (loss) 4,267,082 3,611 4,263,471
Balance at Mar. 31, 2025 11,569,375 $ 58 146,013,449 (1,194,675) (133,249,457)
Balance, shares at Mar. 31, 2025   58,101      
Balance at Dec. 31, 2024 (9,013,430) $ 3 129,697,781 (1,198,286) (137,512,928)
Balance, shares at Dec. 31, 2024   3,204      
Net income (loss) (1,185,464)        
Balance at Sep. 30, 2025 7,516,665 $ 1,727 147,411,616 (1,080,153) (138,816,525)
Balance, shares at Sep. 30, 2025   1,727,421      
Balance at Mar. 31, 2025 11,569,375 $ 58 146,013,449 (1,194,675) (133,249,457)
Balance, shares at Mar. 31, 2025   58,101      
Stock-based compensation 9,741 9,741
Fair value of Series A warrants issued along with sale of common stock (1,340,214) (1,340,214)
Fair value of Series B warrants issued along with sale of common stock (5,406,408) (5,406,408)
Issuance of common stock upon exercise of February 2025 Series B common stock purchase warrants $ 1,669 (1,669)
Issuance of common stock upon exercise of February 2025 Series B common stock purchase warrants, shares   1,669,320      
Transition of warrant derivative liability to equity upon exercise of Series B warrants issued along with February 2025 sale of common stock 5,406,320 5,406,320
Transition of warrant derivative liability to equity of Series A warrants issued along with February 2025 sale of common stock 530,101 530,101
Deemed capital contribution related to modification of notes payable - related party 1,871,994 1,871,994
Net income (loss) (4,489,204) 55,997 (4,545,201)
Balance at Jun. 30, 2025 8,151,705 $ 1,727 147,083,314 (1,138,678) (137,794,658)
Balance, shares at Jun. 30, 2025   1,727,421      
Stock-based compensation 8,885 8,885
Fair value of Series B warrants issued along with sale of common stock
Equity Issuances - Senior Note with detachable warrant September 2025 319,417 319,417
Net income (loss) (963,342) 58,525 (1,021,867)
Balance at Sep. 30, 2025 $ 7,516,665 $ 1,727 $ 147,411,616 $ (1,080,153) $ (138,816,525)
Balance, shares at Sep. 30, 2025   1,727,421